AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|AAPL331.34-1.74 (-0.52%) ▼|ABBV263.04+1.27 (+0.49%) ▲|ABT102.03-1.06 (-1.03%) ▼|ACN193.40-1.60 (-0.82%) ▼|ADBE257.76-7.84 (-2.95%) ▼|AMAT421.17-3.04 (-0.72%) ▼|AMD504.20+10.79 (+2.19%) ▲|AMGN375.65-5.85 (-1.53%) ▼|AMT177.71+0.77 (+0.44%) ▲|AMZN248.42-5.12 (-2.02%) ▼|AVGO339.27-5.45 (-1.58%) ▼|AXP324.43-3.35 (-1.02%) ▼|BA209.69-0.58 (-0.28%) ▼|BAC59.52+0.05 (+0.08%) ▲|BKNG171.32-4.03 (-2.30%) ▼|BLK1,058.66-6.94 (-0.65%) ▼|BMY63.73-0.37 (-0.58%) ▼|BNY154.67-2.99 (-1.90%) ▼|BRK-B516.76+1.81 (+0.35%) ▲|C136.17-0.01 (-0.01%) ▼|CAT783.54-0.46 (-0.06%) ▼|CL87.00-0.89 (-1.01%) ▼|CMCSA24.42-0.46 (-1.85%) ▼|COF206.85+0.17 (+0.08%) ▲|COP141.22+4.55 (+3.33%) ▲|COST901.35-17.56 (-1.91%) ▼|CRM255.65-3.78 (-1.46%) ▼|CSCO110.07+0.01 (+0.01%) ▲|CVS94.49-1.06 (-1.11%) ▼|CVX217.77+5.60 (+2.64%) ▲|DE684.04+2.58 (+0.38%) ▲|DHR209.36+6.11 (+3.01%) ▲|DIS106.42-2.17 (-2.00%) ▼|DUK117.77-1.25 (-1.05%) ▼|EMR147.00-1.30 (-0.88%) ▼|FDX308.26-4.31 (-1.38%) ▼|GD358.60+1.79 (+0.50%) ▲|GE307.05-10.51 (-3.31%) ▼|GEV882.81+8.05 (+0.92%) ▲|GILD146.30+0.71 (+0.49%) ▲|GM85.37-1.79 (-2.05%) ▼|GOOG341.43-4.28 (-1.24%) ▼|GOOGL344.98-4.41 (-1.26%) ▼|GS976.67-11.78 (-1.19%) ▼|HD305.48-5.39 (-1.73%) ▼|HON203.44+2.06 (+1.02%) ▲|IBM248.37-0.72 (-0.29%) ▼|INTC97.14-0.05 (-0.05%) ▼|INTU329.27-9.88 (-2.91%) ▼|ISRG377.16-0.78 (-0.21%) ▼|JNJ267.20+0.88 (+0.33%) ▲|JPM352.49+2.36 (+0.67%) ▲|KO88.71-0.11 (-0.12%) ▼|LIN462.96-1.45 (-0.31%) ▼|LLY1,136.11-2.17 (-0.19%) ▼|LMT533.46+4.08 (+0.77%) ▲|LOW194.61-3.56 (-1.80%) ▼|LRCX270.87-2.62 (-0.96%) ▼|MA573.27-1.15 (-0.20%) ▼|MCD252.78-4.71 (-1.83%) ▼|MDLZ62.10-0.29 (-0.46%) ▼|MDT93.75-0.05 (-0.05%) ▼|META670.24+4.64 (+0.70%) ▲|MMM164.67+2.65 (+1.64%) ▲|MO69.81+0.31 (+0.45%) ▲|MRK143.79-0.21 (-0.15%) ▼|MS206.28-0.30 (-0.15%) ▼|MSFT497.12-8.29 (-1.64%) ▼|MU927.60+3.57 (+0.39%) ▲|NEE81.07-0.56 (-0.69%) ▼|NFLX77.90-2.42 (-3.01%) ▼|NKE36.22-0.83 (-2.24%) ▼|NOW141.90-0.45 (-0.32%) ▼|NVDA212.17+1.21 (+0.57%) ▲|ORCL140.35-4.44 (-3.07%) ▼|PEP135.50-0.84 (-0.62%) ▼|PFE27.55-0.17 (-0.61%) ▼|PG146.67+0.54 (+0.37%) ▲|PLTR172.56-0.75 (-0.43%) ▼|PM194.11-0.75 (-0.38%) ▼|QCOM187.80+7.65 (+4.25%) ▲|RTX195.50+0.16 (+0.08%) ▲|SBUX96.58-2.49 (-2.51%) ▼|SCHW107.79+0.48 (+0.45%) ▲|SO85.95-1.05 (-1.21%) ▼|SPG204.10-0.87 (-0.42%) ▼|T26.72+0.21 (+0.79%) ▲|TMO641.39+28.24 (+4.61%) ▲|TMUS180.47-2.43 (-1.33%) ▼|TSLA356.58-2.39 (-0.67%) ▼|TXN263.43+0.01 (+0.00%) ▲|UBER71.43-1.20 (-1.65%) ▼|UNH375.93-7.62 (-1.99%) ▼|UNP283.99-1.09 (-0.38%) ▼|UPS102.35-0.11 (-0.11%) ▼|USB62.22-0.46 (-0.73%) ▼|V375.62+0.34 (+0.09%) ▲|VZ51.45+0.16 (+0.31%) ▲|WFC89.72+1.01 (+1.14%) ▲|WMT108.09-0.99 (-0.91%) ▼|XOM169.32+4.24 (+2.57%) ▲|
18.3 C
New York
Wednesday, September 16, 2026

Tag: plans

Kiwetinohk announces formal business strategy review

CALGARY, AB, June 23, 2025 /CNW/ - Kiwetinohk Energy Corp. (TSX: KEC) ("Kiwetinohk" or the "Company") announces that it has launched a formal business strategy...

CATL Chairman and CEO Robin Zeng Outlines Vision for Global Zero-Carbon Transition and Deeper Collaboration at Major Conference

CHENGDU, China, June 23, 2025 /PRNewswire/ -- Recently, Dr. Robin Zeng, Chairman and CEO of Contemporary Amperex Technology Co., Limited (CATL), delivered a speech at the...

CATL Chairman and CEO Robin Zeng Outlines Vision for Global Zero-Carbon Transition and Deeper Collaboration at Major Conference

CHENGDU, China, June 23, 2025 /CNW/ -- Recently, Dr. Robin Zeng, Chairman and CEO of Contemporary Amperex Technology Co., Limited (CATL), delivered a speech at the...

Aetna Supports Industry Actions to Simplify Prior Authorization

Company commits to distinctive actions that will make it easier to navigate the health care system, access care, and achieve better healthHARTFORD, Conn., June...

E-Invoicing Could Unlock Nearly £9 Billion for the UK Economy, Avalara Finds

New global research from Avalara and Cebr reveals the transformative power of electronic invoicing adoption in the UK and across five other major marketsProductivity...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

TARRAN at EUROBIKE 2025: try out the first intelligent e-cargo bike T1 Pro & explore the future of smart cycling

FRANKFURT, Germany, June 23, 2025 /PRNewswire/ -- Under the motto "Mind the Bike - Discover What's Next in Smart Cycling", the intelligent mobility company TARRAN...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

Evaluating Income Strategies to Enhance Social Security in Retirement Plans

Social Security is structured to replace approximately 40% of the average retiree's income, necessitating additional income sources to maintain one's standard of living. Annuities...

Deepcoin Integrates TradingView Webhook for Automated Perpetual Trading Execution

GRAND CAYMAN, Cayman Islands, June 23, 2025 /PRNewswire/ -- Deepcoin, a leading cryptocurrency derivatives trading platform, has officially integrated its perpetual trading system with...

Risen Energy Highlights Advancements in Green Manufacturing, Sustainable Development and Corporate Responsibility in 2024 ESG Report

NINGBO, China, June 23, 2025 /PRNewswire/ -- Risen Energy Co., Ltd. (SZSE: 300118), a globally leading renewable energy company, recently released its 2024 Environmental,...

Risen Energy Highlights Advancements in Green Manufacturing, Sustainable Development and Corporate Responsibility in 2024 ESG Report

NINGBO, China, June 22, 2025 /PRNewswire/ -- Risen Energy Co., Ltd. (SZSE: 300118), a globally leading renewable energy company, recently released its 2024 Environmental,...

Yunji Technology Wins Gold with the Congratulations of the Jury, Chinese AI Firm Gains Global Acclaim.

HONG KONG, June 23, 2025 /PRNewswire/ -- This year, the Hong Kong stock market has been performing strongly. Beijing Yunji Technology Co., Ltd. (referred to...

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPlans